News
Important Only
Morning News Call - Canada, May 16
(Morning News Call - Canada edition will not be published on Monday, May 19, on account of the Victoria Day holiday) To access a PDF version of this newsletter, please click hereYou can read Morning News Call Canada via TOPNEWS Canada page.If you would like to receive this newsletter through your em...Reuters
Fri, May 16
Biomarin To Acquire Inozyme Pharma
May 16 (Reuters) - Biomarin Pharmaceutical Inc BMRN.O:BIOMARIN STRENGTHENS ENZYME THERAPY BUSINESS WITH ACQUISITION OF INOZYME PHARMAINOZYME PHARMA INC - BIOMARIN TO BUY INOZYME FOR $270 MILLIONINOZYME PHARMA INC - BIOMARIN REAFFIRMS 2025 FINANCIAL GUIDANCEReuters
Fri, May 16
Circle Internet Group Adds Amerivet Securities, Drexel Hamilton, Mischler Financial Group, Roberts & Ryan To Its List Of Underwriters To IPO
May 16 (Reuters) - CIRCLE INTERNET GROUP ADDS AMERIVET SECURITIES, DREXEL HAMILTON, MISCHLER FINANCIAL GROUP, ROBERTS & RYAN TO ITS LIST OF UNDERWRITERS TO IPOSource text: [ID:n0001193125-25-121234]Further company coverage: [ ]Reuters
Fri, May 16
Nrg Energy If Deal Is Terminated Under Some Circumstances, Co To Pay $400 Million Termination Fee To Ls Power Equity Advisors
May 16 (Reuters) - NRG Energy Inc NRG.N:NRG ENERGY: IF DEAL IS TERMINATED UNDER SOME CIRCUMSTANCES, CO TO PAY $400 MILLION TERMINATION FEE TO LS POWER EQUITY ADVISORSSource text: [ID:n0001104659-25-049673]Reuters
Fri, May 16
Broadway Financial Expects Net Loss Of $1.9 Million For Quarter Ended March 31
May 16 (Reuters) - Broadway Financial Corp BYFC.O:BROADWAY FINANCIAL CORP: EXPECTS NET LOSS OF $1.9 MILLION FOR QUARTER ENDED MARCH 31BROADWAY FINANCIAL CORP: FILES FOR NON-TIMELY 10-Q WITH SECSource text: [ID:n0001140361-25-019371]Reuters
Fri, May 16
Rlx Technology Q1 Gross Margin 28.6%
May 16 (Reuters) - RLX Technology Inc RLX.N:RLX TECHNOLOGY Q1 GROSS MARGIN 28.6%RLX TECHNOLOGY Q1 OPERATING EXPENSES RMB 153.5 MILLIONRLX TECHNOLOGY Q1 GROSS PROFIT RMB 231 MILLIONRLX TECHNOLOGY Q1 ADJUSTED NET INCOME RMB 251.1 MILLIONRLX TECHNOLOGY Q1 REVENUE RMB 808.3 MILLIONRLX TECHNOLOGY Q1 NET ...Reuters
Fri, May 16
Neurogene Announces Evidence-Based Monitoring And Treatment Intended To Reverse Rare Hyperinflammatory Syndrome Associated With High-Dose Aav
May 16 (Reuters) - Neurogene Inc NGNE.O:NEUROGENE ANNOUNCES EVIDENCE-BASED MONITORING AND TREATMENT INTENDED TO REVERSE RARE HYPERINFLAMMATORY SYNDROME ASSOCIATED WITH HIGH-DOSE AAVReuters
Fri, May 16
Star Diamond Corporation Announces Transformative Transaction With Spirit Resources S.A.R.L.
May 16 (Reuters) - Star Diamond Corp DIAM.TO:STAR DIAMOND CORPORATION ANNOUNCES TRANSFORMATIVE TRANSACTION WITH SPIRIT RESOURCES S.A.R.L.STAR DIAMOND CORP - ANNOUNCES FUNDING AGREEMENT WITH SPIRIT RESOURCESSTAR DIAMOND CORP - SPIRIT TO SUBSCRIBE FOR 133.3 MILLION UNITS AT C$0.03 EACHReuters
Fri, May 16
Meg Energy Responds To Strathcona Resources Announcement Of An Intention To Make An Unsolicited Offer
May 16 (Reuters) - MEG Energy Corp MEG.TO:MEG ENERGY RESPONDS TO STRATHCONA RESOURCES LTD.'S ANNOUNCEMENT OF AN INTENTION TO MAKE AN UNSOLICITED OFFERMEG ENERGY CORP - BOARD TO EVALUATE STRATHCONA OFFER IF RECEIVEDReuters
Fri, May 16
Bristol Myers Squibb Receives European Commission Approval For Perioperative Regimen Of Neoadjuvant Opdivo(Nivolumab) And Chemotherapy Followed By Adjuvant Opdivo For Resectable, High-Risk Non-Small Cell Lung Cancer With Pd-L1 Expression ≥1%
May 16 (Reuters) - Bristol-Myers Squibb Co BMY.N:BRISTOL MYERS SQUIBB RECEIVES EUROPEAN COMMISSION APPROVAL FOR PERIOPERATIVE REGIMEN OF NEOADJUVANT OPDIVO® (NIVOLUMAB) AND CHEMOTHERAPY FOLLOWED BY ADJUVANT OPDIVO FOR RESECTABLE, HIGH-RISK NON-SMALL CELL LUNG CANCER WITH PD-L1 EXPRESSION ≥1%Reuters
Fri, May 16
